Validation of the prognostic and predictive value of class III beta tubulin (TUBB3) for adjuvant chemotherapy (ACT) in completely resected non-small cell lung cancer (R-NSCLC): results from four randomized trials

被引：0
|
作者：
Reiman, Tony [1 ]
Seve, Pascal [2 ]
Veillard, Anne-Sophie [3 ]
Soria, Jean-Charles [3 ]
Rosell, Rafael [4 ]
Taron, Miquel [4 ]
Graziano, Stephen [5 ]
Kratzke, Robert [8 ]
Seymour, Lesley [6 ]
Shepherd, Frances [9 ]
Pignon, Jean-Pierre [3 ]
Lai, Raymond [7 ]
机构：
[1] St Johns Hosp, St John, NB, Canada
[2] Hop Hotel Dieu, F-69288 Lyon, France
[3] Inst Gustave Roussy, Villejuif, France
[4] Catalan Inst Oncol, Badalona, Spain
[5] SUNY Syracuse, Syracuse, NY USA
[6] NCIC Clin Trials Grp, Kingston, ON, Canada
[7] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[8] Univ Minnesota, Minneapolis, MN USA
[9] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S298 / S298
页数：1
相关论文
共 50 条
  • [1] Prognostic value of class III b-tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin-based chemotherapy (CT): A validation study on three randomized trials
    Reiman, T.
    Seve, P.
    Vataire, A.
    Dunant, A.
    Rosell, R.
    Graziano, S.
    Seymour, L.
    Pirker, R.
    Lai, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials
    Reiman, T.
    Lai, R.
    Veillard, A. S.
    Paris, E.
    Soria, J. C.
    Rosell, R.
    Taron, M.
    Graziano, S.
    Kratzke, R.
    Seymour, L.
    Shepherd, F. A.
    Pignon, J. P.
    Seve, P.
    ANNALS OF ONCOLOGY, 2012, 23 (01) : 86 - U10
  • [3] Beta-III tubulin (TUBB3) as a marker of local dissemination of non-small cell lung cancer
    Bogush, T.
    Mamichev, I.
    Dudko, E.
    Bogush, E.
    Davydov, M.
    Polotsky, B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S602 - S603
  • [4] A prospective randomized study of adjuvant chemotherapy in completely resected stage III-N2 non-small cell lung cancer
    Zheng Shi Ying
    Jiang Dong
    Li Hong
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S518 - S518
  • [5] Randomized Phase III Trial of Adjuvant Chemotherapy with or without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): Results of E1505
    Wakelee, Heather A.
    Dahlberg, Suzanne E.
    Keller, Steven M.
    Tester, William J.
    Gandara, David R.
    Graziano, Stephen L.
    Adjei, Alex
    Leighl, Natasha
    Aisner, Seena C.
    Rothman, Jan M.
    Patel, Jyoti
    Sborov, Mark D.
    Mcdermott, Sean R.
    Perez-Soler, Roman
    Traynor, Anne M.
    Butts, Charles
    Evans, Tracey
    Horn, Leora
    Ramalingam, Suresh S.
    Schiller, Joan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S796 - S796
  • [6] LACE-BIO POOLED ANALYSIS OF THE PROGNOSTIC AND PREDICTIVE VALUE OF KRAS MUTATION IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER (NSCLC)
    Tsao, M.
    Hainaut, P.
    Bourredjem, A.
    Janne, P. A.
    Pignon, J.
    Douillard, J.
    Soria, J.
    Seymour, L.
    Shepherd, F. A.
    ANNALS OF ONCOLOGY, 2010, 21 : 63 - 63
  • [7] Selection for adjuvant chemotherapy in completely resected stage I non-small cell lung cancer: external validation of a Chinese prognostic risk model
    Kumbasar, Ulas
    Raubenheimer, Hilgardt
    Al Sahaf, May
    Asadi, Nizar
    Cufari, Maria Elena
    Proli, Chiara
    Perikleous, Periklis
    Niwaz, Zakiyah
    Beddow, Emma
    Anikin, Vladimir
    McGonigle, Niall
    Jordan, Simon
    Ladas, George
    Dusmet, Michael
    Lim, Eric
    JOURNAL OF THORACIC DISEASE, 2016, 8 (01) : 140 - 144
  • [8] Advanced age is associated with lack of administration of adjuvant chemotherapy for completely resected stage IB-III non-small cell lung cancer (NSCLC)
    Riely, Gregory J.
    Seshan, V. E.
    Azzoli, C. G.
    Kris, Mark G.
    Rusch, Valerie W.
    Park, Bernard K.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S454 - S454
  • [9] Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer
    Tsuboi, M
    Kato, H
    Nagai, K
    Tsuchiya, R
    Wada, H
    Tada, H
    Ichinose, Y
    Fukuoka, M
    Jiang, HY
    ANTI-CANCER DRUGS, 2005, 16 (10) : 1123 - 1128
  • [10] ADJUVANT CHEMOTHERAPY FOR COMPLETELY RESECTED STAGE-III NON-SMALL-CELL LUNG-CANCER - RESULTS OF A RANDOMIZED PROSPECTIVE-STUDY
    OHTA, M
    TSUCHIYA, R
    SHIMOYAMA, M
    SAWAMURA, K
    MORI, T
    MIYAZAWA, N
    SUEMASU, K
    WATANABE, Y
    TOMITA, M
    TERASHIMA, M
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1993, 106 (04): : 703 - 708
12345